Bio3 Research intends to identify,
develop and bring to commercial fruition new or highly innovative therapeutical
agents in diseases related to HMGB1 protein over-expression and HMGB1
biological properties.
Strong over-expression of HMGB1 it has been detected in:
Restenosis; Atherosclerosis - induced by angioplasty; Atherosclerotic plaque;
HMGB1 proliferation activity has also been tested in:
Connective tissues repair.
Bio3 News...
Bio3 Research has recently been granted from USPTO the
US
patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for
the treatment of Cardiovascular Disorders…
